Technical Analysis for ZYNE - Zynerba Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.92 -2.00% -0.08
ZYNE closed down 2.0 percent on Wednesday, January 16, 2019, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ZYNE trend table...

Date Alert Name Type % Chg
Jan 16 NR7 Range Contraction 0.00%
Jan 16 Inside Day Range Contraction 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 15 Spinning Top Other -2.00%
Jan 15 Wide Bands Range Expansion -2.00%
Jan 15 Overbought Stochastic Strength -2.00%
Jan 14 Weak + Overbought Other 1.03%
Jan 14 Wide Bands Range Expansion 1.03%
Jan 14 Overbought Stochastic Strength 1.03%
Jan 14 Down 3 Days in a Row Weakness 1.03%

Older signals for ZYNE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates, including ZYN002 and ZYN001, which represent cannabinoid therapeutics for several indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies, ZYN002's permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies, ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.
Is ZYNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.98
52 Week Low 2.75
Average Volume 304,392
200-Day Moving Average 7.6022
50-Day Moving Average 4.5136
20-Day Moving Average 3.599
10-Day Moving Average 4.015
Average True Range 0.3392
ADX 22.67
+DI 21.44
-DI 22.2655
Chandelier Exit (Long, 3 ATRs ) 3.4824
Chandelier Exit (Short, 3 ATRs ) 3.7676
Upper Bollinger Band 4.5837
Lower Bollinger Band 2.6143
Percent B (%b) 0.66
BandWidth 54.720756
MACD Line -0.1096
MACD Signal Line -0.227
MACD Histogram 0.1174
Fundamentals Value
Market Cap 51.97 Million
Num Shares 13.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -1.51
Price-to-Sales 0.00
Price-to-Book 1.77
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.18
Resistance 3 (R3) 4.20 4.15 4.13
Resistance 2 (R2) 4.15 4.08 4.13 4.12
Resistance 1 (R1) 4.03 4.04 4.01 4.01 4.10
Pivot Point 3.98 3.98 3.96 3.96 3.98
Support 1 (S1) 3.86 3.91 3.84 3.84 3.74
Support 2 (S2) 3.81 3.87 3.79 3.72
Support 3 (S3) 3.69 3.81 3.71
Support 4 (S4) 3.67